Summit Therapeutics (SMMT) Equity Average (2016 - 2025)
Historic Equity Average for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $225.9 million.
- Summit Therapeutics' Equity Average fell 2864.05% to $225.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.9 million, marking a year-over-year decrease of 2864.05%. This contributed to the annual value of $233.2 million for FY2024, which is 12825.99% up from last year.
- According to the latest figures from Q3 2025, Summit Therapeutics' Equity Average is $225.9 million, which was down 2864.05% from $301.9 million recorded in Q2 2025.
- Summit Therapeutics' 5-year Equity Average high stood at $413.3 million for Q4 2024, and its period low was $57.9 million during Q2 2022.
- Its 5-year average for Equity Average is $156.9 million, with a median of $110.9 million in 2021.
- Its Equity Average has fluctuated over the past 5 years, first crashed by 5313.91% in 2024, then soared by 50136.67% in 2025.
- Over the past 5 years, Summit Therapeutics' Equity Average (Quarter) stood at $92.8 million in 2021, then soared by 40.05% to $130.0 million in 2022, then plummeted by 31.87% to $88.5 million in 2023, then skyrocketed by 366.86% to $413.3 million in 2024, then tumbled by 45.36% to $225.9 million in 2025.
- Its last three reported values are $225.9 million in Q3 2025, $301.9 million for Q2 2025, and $366.5 million during Q1 2025.